Shares of drugmaker Cipla Ltd. surged over 2.5% on Friday, July 25 after its results for the June quarter were a beat on most parameters.Cipla’s US sales for the June quarter stood at $226 million, which was higher than the CNBC-TV18 poll estimate, that ranged between $218 million and $221 million,
Revenue for the quarter increased by 3.9% on a year-on-year basis to ₹6,957 crore, which is marginally lower than the CNBC-TV18 poll of ₹7,106 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter stood at ₹1,778 crore, which is a growth of 3.6% from the year-ago quarter and marginally higher than the CNBC-TV18 poll estimate of ₹1,714 crore.
EBITDA margin stood at 25.6%, which is the same as the base quarter and higher compared to the CNBC-TV18 poll estimate of 24.1%. Cipla’s margins are higher than the company’s financial year 2026 guidance, which is between 23.5% to 24.5%.Cipla’s One-India business delivered growth of 6% from last year and crossed the ₹3,000 crore mark for the first time in the opening quarter of any financial year.
Revenue for the quarter increased by 3.9% on a year-on-year basis to ₹6,957 crore, which is marginally lower than the CNBC-TV18 poll of ₹7,106 crore.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter stood at ₹1,778 crore, which is a growth of 3.6% from the year-ago quarter and marginally higher than the CNBC-TV18 poll estimate of ₹1,714 crore.
EBITDA margin stood at 25.6%, which is the same as the base quarter and higher compared to the CNBC-TV18 poll estimate of 24.1%. Cipla’s margins are higher than the company’s financial year 2026 guidance, which is between 23.5% to 24.5%.Cipla’s One-India business delivered growth of 6% from last year and crossed the ₹3,000 crore mark for the first time in the opening quarter of any financial year.
The One Africa business grew by 11% in US Dollar terms during the quarter.
“Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained its leadership position,” Cipla MD & Global CEO Umang Vohra said.
Shares of Cipla are trading 3.3% higher after the results announcement at ₹1,537. With this, the stock has also turned positive on a year-to-date basis.
First Published: Jul 25, 2025 1:39 PM IS
